.jpg "Amedisys (NASDAQ: AMED)")
In a report released today, Michael Wiederhorn from Oppenheimer maintained a Buy rating on Amedisys (AMED). The company’s shares opened today at $125.18.
According to TipRanks.com, Wiederhorn is a top 100 analyst with an average return of 14.4% and a 66.4% success rate. Wiederhorn covers the Services sector, focusing on stocks such as Cross Country Healthcare, Addus Homecare Corp, and Community Health.
Amedisys has an analyst consensus of Moderate Buy, with a price target consensus of $135.50, which is an 8.2% upside from current levels. In a report issued on March 4, RBC Capital also maintained a Buy rating on the stock with a $133 price target.
See today’s analyst top recommended stocks >>
Based on Amedisys’ latest earnings release for the quarter ending December 31, the company reported a quarterly net profit of $27.46 million. In comparison, last year the company had a GAAP net loss of $3.85 million.
Based on the recent corporate insider activity of 58 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Amedisys, Inc. engages in the provision of healthcare services. It operates through the following business segments: Home Health, Hospice, and Personal Care. The Home Health segment delivers services in the homes of individuals who may be recovering from an illness, injury, or surgery.
